0.82 ± 0.17 gimol I') as evidenced by a lower 99mTc-NGA-accumulation in the liver resulting also in a significantly (P<0.001) lower RFLV (739 ± 348 vs 1336 ± 184 ml). In four amonafide-treated patients (800 mg m-2 intravenous infusion over 3 h) approximately one week after one chemotherapy cycle a significant (P<0.05) increase in HBP-concentration (0.56 ± 0.10 vs 0.72 ± 0.06 Lmol l-) of the liver was found corresponding with an increase in RVLF (546 ± 297 vs 670 ± 265 ml). These regulatory mechanisms at the HBP level measured in vivo provide further evidence that 99'Tc-NGA should have promise as a clinically useful receptor radiopharmaceutical for both quantification of liver function and assessment of liver morphology.
One of the most challenging fields in nuclear medicine is the use of specific receptor radiopharmaceuticals (Eckelman et al., 1979) . These tracers have been successfully applied in oncology, such as for the detection of endocrine tumours using somatostatin analogs (Krenning et al., 1989) , specific receptor radiotracers for the brain (Wagner et al., 1983) , radiolabelled epidermal growth factor in gynaecology (Schatten et al., 1990) , radiolabelled oestrogen analogs in breast cancer (Pavlik et al., 1990) or galactose-terminated neoglycoalbumin (NGA) in primary and secondary liver cancer (Virgolini et al., 1989b) . 9'Tc-NGA is one of the first chemically synthetised receptor radiopharmaceuticals introduced for in vivo use in humans (Vera et al., 1984; Stadalnik et al., 1985; Virgolini et al., 1989a Virgolini et al., ,b, 1991 Virgolini et al., , 1992 . It is a glycoprotein with galactose residues which upon injection into the bloodstream is exclusively trapped by hepatocytes on the basis of specific interaction with the cell surface-bound hepatic binding protein (HBP) (Stockert & Morell, 1983) . Preclinical studies have confirmed the receptor-binding properties of 99'Tc-NGA (Virgolini et al., 1989a) . The unique specific interaction of NGA with HBP provided the basis of kinetic modelling 1991a) . Hence, the simulation of 9'9Tc-NGA binding onto hepatocytes was extended to patients with various liver disease (Stadalnik et al., 1985; Virgolini et al., 1991 Virgolini et al., , 1992 . In these studies hepatic function was determined from global HBP-receptor density and hepatic blood flow Q. Changes in either of these two independent physiologic parameters are reflected by the rate of hepatic accumulation. Delivery of 9'Tc-NGA is determined by the magnitude of the hepatic blood flow Q, and the rate of the HBP-mediated binding process is governed by the affinity of 99'Tc-NGA for the receptor and by HBP- concentration. Thus, changes in hepatic blood flow Q or HBP-concentration will be reflected by the liver time-activity curves. The approach has been successfully applied as a new technique for assessment of functional liver cell mass (in addition to liver morphological S.P.E.C.T.-scintigraphy) in patients with hepatocellular carcinoma (Virgolini et al., 1989b) , liver cirrhosis and fibrosis (Virgolini et al., 1991) , viral hepatitis (Virgolini et al., 1992) , and in patients undergoing liver transplantation (Woodle et al., 1987) .
A decade ago direct evidence for reduction of HBPconcentration as a consequence of hepatocellular pathology was reported by Stockert and Becker (1980) . We also found a reduced HBP-concentration in patients with primary or secondary hepatic cancer in vivo and in vitro (Virgolini et al., 1989a,b) . This study now investigated the in vivo binding of 99'Tc-NGA to HBP in patients with advanced breast cancer with and without liver metastases. The results suggest that serial studies may document changes in hepatocellular function in patients undergoing chemotherapy for breast cancer.
Materials and methods

Subjects
The application of NGA to humans was approved by the Ethical Committee of the Faculty of Medicine, University of Vienna. All patients reported here were women and had histologically documented advanced breast cancer. 'Tc-NGA-scintigraphic studies were performed as an addendum to routine ultrasound, 99'Tc-sulfur colloid scintigraphy, computed tomography and frequent laboratory examinations in order to assess liver morphology and functional hepatic mass. Seven women had no clinical evidence of liver metastases, whereas the above mentioned clinical investigations strongly suggested secondary involvement of the liver in 15 others.
In order to further evaluate the significance of the 9'Tc-NGA-scintigraphy in patients with breast cancer, eight women receiving palliative chemotherapy with amonafide (nafidimide, benzisoquinoline-dione; Knoll AG, Ludwigshafen, Germany) in a Phase II clinical trial (Scheithauer et al., 1991) were designed to undergo serial 9'Tc-NGA-scintigraphic studies. These patients had histologically confirmed progressive advanced breast cancer, refractory to prior hormone and/or first-line chemotherapy. Amonafide was given intravenously at a starting dose of 800mgm-2 over 3 h. The schedule of drug administration was a single drug infusion given every 28 days.
Radiopharmaceutical synthesis and labelling
The synthesis and labelling of NGA was described in detail previously (Virgolini et al., 1989a Radiochemical purity was generally >97%, i.e. the "mTc-NGA peak contained >97% of total 99mTc on the electrophoresis strip. The labelling yield after filtration through low-protein-absorption membranes amounted to about 95%, in vitro-stability at room temperature exceeded through more than 10 h.
Gamma camera imaging
In all patients, the in vivo-binding of 99mTc-NGA to HBP was estimated. The exact dose given to a patient amounted to 140 ± 15 MBq/3.5 mg NGA (50 nmol). The patients were placed in a supine position under a gamma camera (Searle Radiographics Inc., Des Plaines, IL) connected to a data processor (PDP 11/34, Digital Equipment Int. Ltd., Galway, Ireland). The gamma camera was equipped with a low energy collimator (140 KeV; Searle, Radiographics, Inc.). Computer acquisition of gamma-camera data was performed at a rate of two frames/minute and a matrix of 64 x 64 pixels. Timeactivity curves were recorded over precordium and liver. The total acquisition time was 30 min.
Two to 5 min after injection of 99"Tc-NGA a blood sample (1 ml) was drawn and transferred into a preweighed plastic tube. The blood concentration of 99mTc-NGA was calculated using the activity/gram of this blood sample and a diluted standard of the labelled product (1:5000). The blood sample was used to relate the counts measured under the gammacamera to the absolute amount of injected tracer.
After completion of the dynamic study of NGA-uptake the patients underwent a S.P.E.C.T.-examination of the liver using a dual head rotating gamma-camera equipped with a low energy collimator (ROTA-camera, Siemens GmbH, Erlangen). Using a matrix of 128 x 128 pixels, 60 pictures were obtained within a total exposure time of 10 min (angle 6°/1 turn 10 s).
Analyses
Gamma camera data (dynamic study) The pharmacokinetics of NGA follow the model designed and extensively validated by Vera et al., 1985 Vera et al., , 1991a Kudo et al., 1991; Virgolini et al., 1989b Virgolini et al., , 1991a . It consists of the hemodynamic subsystem which delivers the ligand to the target organ, and of the receptor-binding subsystem in which the formation of the receptor-ligand complex within the target organ takes place. A further path allowing for the utilisation of the ligand-receptor complex consists of the unidirectional catabolic reaction of the complex into the metabolic end product. Following this model, system state equations can be obtained of the kinetic system which are mathematically represented as a system of first order nonlinear differential equations. Further shown in the model are two observers designated Y, and Y2. In practice, observer Y1 looks at the time course of radioactivity in the extrahepatic blood which can be obtained by a region of interest over the precordial area. Observer Y2 measures the radioactivity in the area of the liver which is the sum of two components, the radioactivity of the free ligand and the radioactivity of the ligand-receptor complex.
The primary input data for the analysis of the kinetic parameters are the time-activity curve of the radioactivity in a region containing the liver representing Y2 of the model and the time-activity curve obtained over a precordial region representing YI. This data together with the blood count results are entered into a program which estimates system states and system parameters iteratively. The program runs on a MicrovaxIl computer and produces as result both the graphic representation of the experimental and the fitted curves and additional numeric output of the system parameters, the most important of which are the concentration of HBP in the liver and the forward binding rate constant Kb for the reaction of the ligand with the receptor in the liver. Furthermore, the program gives estimates on the goodness of fit and of the errors for the various parameters. It should be mentioned that even on a relatively fast computer such as the Microvaxll the analysis for one patient needs about half an hour of computing time.
Gamma camera (S.P.E.C.T.-study) Transverse slices from the S.P.E.C.T.-study were used to estimate the residual functional liver volume (RFLV). The liver volume was determined by applying a fixed cutoff threshold of 37% of the maximum pixel value. After thresholding the number of pixels occupied by the liver was computed. The procedure was carried out for each slice in which the liver was visible after thresholding. All areas were then added and multiplied by the pixel volume in order to obtain the volume of the liver (given in ml). The pixel dimensions in millimeters were obtained from distance calibration measurements carried out regularly as part of the quality control procedures for the gamma camera.
The thresholding method used to determine the liver volume from the S.P.E.C.T. images measures the functional liver volume insofar in that uptake values exceeding 37% are considered as belonging to the functional liver tissue. The thresholding technique implies that solid metastases within the liver are excluded from the functional volume if they exceed a diameter of 1 cm. This is related to the S.P.E.C.T. acquisition technique (slice thickness of 6.3 mm). The thresholding technique as such (Tauxe et al., 1982; Strauss et al., 1984 ) is known to give accurate values especially for the determination of liver volume due to negligible background activity.
*The threshold used was determined empirically from phantom experiments in preliminary studies. In those, a liver phantom with a known volume of 650 ml was suspended in a water tank of dimensions 40 x 40 x 20 cm. Water tank and liver phantom were filled with radioactive solutions with different ratios of concentrations and the threshold determined for which the measured liver volume was closest to the true liver volume.
Statistical analysis
Statistical comparison between the means was made by the Student's t-test for unpaired data at a confidence level of 95%. Weighted linear regression was used to calculate the slope and y-intercept of each correlation plot during the follow-up period. Values are presented as means + standard deviations.
Results
Biodistribution
In vivo-simulation of 99mTc-NGA-kinetics allowed quantification of9'Tc-NGA-binding to HBP. In both patients with normal hepatic function (Virgolini et al., 1989b; Virgolini et al., 1991 Virgolini et al., , 1992 and patients with liver metastases 99nTc-NGA was exclusively trapped by the liver. At 10 min after injection liver uptake was >95% of the administered dose in patients with normal livers. No significant difference was found for patients with documented liver metastases. One hour after injection of 99mTc-NGA the plasma activity ranged from 1 to 2%. At 24 h after injection, visible tracer accumulation (about 30-50%) was found over the intestine showing that the major excretory route for NGA is the biliary system. At that time urinary excretion was <2% suggesting that the stability of the receptor-radiopharmaceutical is such that urinary excretion of degradation products is only minimal.
Binding of NGA to HBP -simulation study In the seven women without liver metastases (Table I) (Virgolini et al., 1989b; Virgolini et al., 1991 Virgolini et al., , 1992 . With the exception of one patients (Table I , H.J.) a good matching of actual HBPvalues (dynamic study) with the estimated liver volume (S.P.E.C.T.-study) as well as the laboratory values was found. The forward binding rate constant Kb as well as the hepatic blood flow Q were also in the lower normal range.
In 15 women (Table II) ultrasound, 99Tc-sulfur colloid scintigraphy, and/or computed tomography strongly sug- (Scheithauer et al., 1989 Out of the seven patients on polychemotherapy with 5-fluoro-uracil (FU)/leucovorin (LV)/mitomycin C (MMC) only two could be monitored a second time (Table V) . Again, in both patients a small increase of HBP-density was observed after one chemotherapy cycle.
Binding of NGA to HBP -morphological study via S.P.E.C.T.
Liver morphology was studied by S.P.E.C.T.-scintigraphy. In patients without liver metastases homogeneous uptake of 99'Tc-NGA by the liver was found. In those with liver metastases small 'cold spots' presented the liver malignancy as already reported previously (Virgolini et al., 1989b) . All 9'Tc-NGA-images were comparable to conventional liver images obtained by 9'9Tc-sulfur colloid. The estimated RFLV was significantly (P <0.01) lower in patients with liver metastases as compared with those without liver metastases (739 ± 348 vs 1336 ± 184 ml). Treatment with amonafide increased the RFLV from 546 ± 297 to 670 ± 265 ml (P = 0.07).
Discussion
Several receptor-binding radiopharmaceuticals have been introduced for the in vivo evaluation of receptor density and binding affinity (Eckelman et al., 1979; Krenning et al., 1989; Wagner et al., 1983; Schatten et al., 1990; Pavlik et al., 1990; Virgolini et al., 1989b) , and a variety of nuclear medicine techniques have been implemented to be useful in this aspect (Wagner et al., 1983; Vera et al., 1985; 1991a; Farde et al., 1986; Logan et al., 1987) . A valid analytic assessment of receptor biochemistry via kinetic modelling 1991a) was applied for this study. As the use of S.P.E.C.T. and P.E.T. increases in oncology, we obtained the S.P.E.C.T.-quantified residual functioning liver volume (RFLV) for a comparative evaluation of 99mTc-NGAuptake.
The results obtained in this study suggest that 99"Tc-NGA kinetic imaging as well as S.P.E.C.T.-imaging may provide a new noninvasive means for the diagnosis of metastatic liver cancer. The methodology could provide valuable data not only for the morphological diagnosis but also for the extent of metastases formation in the human liver, and thus residual functional liver cell mass. The more infiltrated the liver the lower the estimated NGA-receptor (i.e. HBP) concentration, or, the RFLV. Those patients without liver metastases (Table   I ) had a higher HBP concentration estimated from the time activity curves as well as a higher S.P.E.C.T.-estimated RFLV as compared with those patients with liver metastases (Table II) . In general, a good correlation between S.P.E.C.T.-estimated RFLV and dynamic imaging of NGA-binding was found. However, in one patient (H.J., Table I ) with a relatively low HBP concentration of 0.51 iLmol 1', a relatively high RFLV of 1574 ml was calculated. The mean- (Scheithauer et al., 1991) shows that the technique applied is sensitive enough to measure changes in HBP receptor density in vivo. In Phase I clinical trials in patients with prostatic carcinoma (Craig et al., 1989) and in Phase II studies in advanced breast cancer (Scheithauer et al., 1991; Constanze et al., 1989) amonafide was shown to be an active drug with therapeutic potential. When applied to humans the dose limiting toxicity observed was myelosuppression, with rapid recovery from granulocytopenia and thrombocytopenia allowing a 3-to 4-week drug administration schedule. In our study increase in HBP was observed approximately 2 weeks after one chemotherapy cycle. This increase was well matched with actual laboratory values for hepatic function. As amonafide is a DNA intercalating agent (Waring et al., 1979) which inhibits protein and nucleotide synthesis (Andersson et al., 1987 ) the basis for an increase of HBP-concentration could not be de-novo synthesis of receptor protein. As we observed no effect of amonafide on hepatic blood flow Q a direct action of the drug on the receptor binding subsystem seems to be close. One explanation for an increased HBP density after therapy with amonafide could also be the recycling of HBP to the cell surface which has been shown in in vitro studies (Steer & Ashwell, 1980) previously. This could result in an increased binding of 9'9Tc-NGA onto the hepatocytes. Circulating binding inhibitors (Marshall et al., 1978) that are present in the plasma of patients with carcinomas could be altered by administration of amonafide. The observed increase of the affinity constant Kb could also mean an improved binding of NGA to the same amount of HBP-receptors. In parallel, the estimated RFLV via S.P.E.C.T.-study was not significantly increased, although improved. This result might be a consequence of the small number of patients in whom a second evaluation could be performed, as in general a good correlation between S.P.E.C.T.-estimated RFLV and dynamic imaging of NGAbinding was found. It should be mentioned that the thresholding technique as such (Tauxe et al., 1982; Strauss et al., 1984 ) is known to give accurate values especially for the determination of liver volume due to negligible background activity. The thresholding method used to determine the RFLV from the S.P.E.C.T. images implies that large deposits within the liver are excluded from the functional volume evaluation. Small lesions that do not resolve on the transverse slices of the S.P.E.C.T.-study can not be excluded from the evaluation. These might 'dilute' the true RFLV. We believe, however, that the increased RFLV measured after chemotherapy as compared to the RFLV before chemotherapy is not a side effect of such a possible dilution effect, but represents a direct effect of (chemo)therapy on liver metastases.
In conclusion, 99Tc-NGA functional liver imaging may provide a new noninvasive means for the selection of medical or surgical management in patients with cancer. The changes found in patients after amonafide treatment might suggest the use for this technique in assessing chemotherapy. It would be interesting to see whether this technique would detect liver metastases before standard morphological studies or laboratory liver function tests become abnormal. Determination of HBP activity with a highly specific tracer may provide a valuable measure of hepatic injury and recovery, and could thus provide further insights into receptor regulation during disease states.
